

## Special Issue

# Natural Products to Prevent Cancer Progression

### Message from the Guest Editor

Cancer is an ailment that engages cells' irregular growth with the potential to invade and metastasize to other body portions. The perpetual augmentation in cancer incidence worldwide, along with rising troubles with drug resistance and recurrence, drives the escalating interest in searching for various strategies for cancer prevention. Chemoprevention uses natural, synthetic or biological agents to avoid or suppress the initial phase of carcinogenesis to inhibit the premalignant cells. Chemoprevention is a comparatively safe and cost-saving method because cancer can be averted by changing dietary habits. Drug-related toxicity is a cardinal obstacle for currently available chemotherapeutic drugs. Nevertheless, using natural compounds for cancer prevention may lower drug toxicity. The attention in chemoprevention has increased mainly with a gradual uncovering of cancer biology, recognition of molecular gene targets and good accomplishment in breast, prostate and colon cancer prevention. In this Issue, we will accept all manuscripts involving natural or biological agents with defined molecular compounds, which prevent or suppress all the stages of various cancers.

---

### Guest Editor

Prof. Dr. Ting-Feng Wu

Department of Biotechnology and Food Technology, Southern Taiwan University of Science and Technology, Tainan 710, Taiwan

---

### Deadline for manuscript submissions

closed (29 February 2024)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/158881](https://mdpi.com/si/158881)

*Biomedicines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).